目的 探討鹽酸坦洛新緩釋片聯(lián)合前列倍喜膠囊治療前列腺炎的臨床療效。方法 選取2016年5月-2017年5月四川石油管理局總醫(yī)院收治的前列腺炎患者64例為研究對(duì)象，將所有患者隨機(jī)分為對(duì)照組和治療組，每組各32例。對(duì)照組患者口服前列倍喜膠囊，6粒/次，3次/d。治療組患者在對(duì)照組治療的基礎(chǔ)上口服鹽酸坦洛新緩釋片，1片/次，1次/d。兩組患者均連續(xù)治療1個(gè)月。觀察兩組的臨床療效，比較兩組的NIH-CPSI積分、白細(xì)胞（WBC）和卵磷脂小體。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為78.13%、96.88%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組NIH-CPSI積分顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組NIH-CPSI積分明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組WBC水平顯著降低，卵磷脂小體水平顯著升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 鹽酸坦洛新緩釋片聯(lián)合前列倍喜膠囊治療前列腺炎具有較好的臨床療效，可改善患者臨床癥狀和相關(guān)指標(biāo)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Tamsulosin Hydrochloride Sustained Release Tablets combined with Qianliebeixi Capsules in treatment of prostatitis. Methods Patients (64 cases) with prostatitis in General Hospital of CNPC Sichuan Administration from May 2016 to May 2017 were randomly divided into control and treatment groups, and each group had 32 cases. Patients in the control group were po administered with Qianliebeixi Capsules, 6 grains/time, three times daily. Patients in the treatment group were po administered with Tamsulosin Hydrochloride Sustained Release Tablets on the basis of the control group, 1 tablet/time, once daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and NIH-CPSI scores, (white blood cell) WBC, and lecithin bodies in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.13% and 96.88%, respectively, and there was difference between two groups (P<0.05). After treatment, NIH-CPSI scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the NIH-CPSI score in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of WBC in two groups were significantly decreased, but the levels of lecithin bodies in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Tamsulosin Hydrochloride Sustained Release Tablets combined with Qianliebeixi Capsules has clinical curative effect in treatment of prostatitis, can improve clinical symptoms and related indexes, which has a certain clinical application value.